GlassScriptPhysician profile
Katia V Brown
NPI 1093787194
$8,581.93
in general payments reported to CMS, 2019-2025
22 companies · $1,781 in 2025
The $1,781 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $611 · 2021: $1,469 · 2022: $1,388 · 2023: $1,519 · 2024: $1,137 · 2025: $1,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,435.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,078.23 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $1,108.94 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Janssen Biotech, INC. | $913.20 | 2019-2023 | Symtuza |
| Abbvie INC. | $699.62 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Shionogi INC | $596.06 | 2020-2025 | Fetroja |
| Gilead Sciences, INC. | $574.81 | 2019-2025 | Biktarvy |
| Insmed, INC. | $495.44 | 2022-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $494.41 | 2019-2025 | Nuzyra |
| Cumberland Pharmaceuticals, INC. | $394.84 | 2019-2025 | Vibativ |
| Melinta Therapeutics, LLC | $295.18 | 2020-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Theratechnologies INC. | $221.15 | 2020-2025 | Trogarzo, Egrifta |
| Aimmune Therapeutics, INC. | $179.89 | 2024-2025 | Vowst, Zenpep |
| Astellas Pharma US INC | $145.67 | 2019-2025 | Cresemba |
| La Jolla Pharmaceutical Company | $93.62 | 2024-2025 | Xacduro, Zevtera |
| Ferring Pharmaceuticals INC. | $80.91 | 2023-2024 | Rebyota |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $72.34 | 2020-2022 | |
| Dynavax Technologies Corporation | $29.97 | 2020-2022 | |
| Nabriva Therapeutics, Plc | $27.49 | 2020-2021 | |
| Seqirus USA INC | $26.11 | 2025 | Flucelvax, Fluad |
| Pfizer INC. | $21.82 | 2025 | |
| Vyera Pharmaceuticals, LLC | $17.78 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katia Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.